Endocare adds PSA test to urology workstation:
This article was originally published in Clinica
Executive Summary
Endocare has signed a five-year agreement with privately owned Qualigen, to add its point-of-care total PSA test to Endocare's urology diagnostic workstation. The agreement offers one year of exclusivity with further renewals. The FDA-approved 15 minute test is the first of a series that will assist in Endocare's plan to become a total solutions provider for prostate and urological disease, the company claims.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.